Literature DB >> 29113269

The expression and significance of histone lysine methylation in endometrial cancer.

Qing Li1, Nan Jia1, Xiang Tao2, Keqin Hua1,3, Weiwei Feng1,3.   

Abstract

Histone modifications of lysine residues have been implicated as having diagnostic and/or prognostic significance in numerous types of cancer. In the present study, the significance of the histone H3 methylation of lysine 4 (H3K4) and lysine 27 (H3K27) were investigated in endometrial cancer. Specifically, immunohistochemical analysis was used to detect the cellular expression levels of H3K27 trimethylation (H3K27me3), H3K4 trimethylation (H3K4me3) and H3K4 dimethylation (H3K4me2) in glandular epithelial tissues and stromal tissues. The association between the methylation levels of histone markers and clinicopathological parameters were analyzed. The results demonstrated that in epithelial cells, H3K4me2 and H3K4me3 exhibited the highest levels in endometrial cancer, followed by precancerous lesions and a normal endometrium. Low expression levels of H3K4me2 in glandular epithelium of endometrial cancer were significantly associated with a clinical early International Federation of Gynecology and Obstetrics stage (P=0.006). For stromal tissues, the expression level of H3K27me3 in Type 1 endometrial cancer was significantly lower compared with that in the normal endometrium (P=0.043) and precancerous lesions (P<0.001). The expression level of H3K4me2 was significantly lower in the stroma of Type 1 and 2 cancer compared within the normal endometrium (P=0.005). A low H3K4me3 expression level in the stroma of endometrial cancer tissues was associated with P53-negativity (P=0.032). In conclusion, the cellular expression levels of histone H3 methylation were differentially presented in glandular epithelial and stromal elements in endometrial tissues. A low expression level of activation marker H3K4me2 in glandular epithelium defined a subset of patients with early-stage endometrial adenocarcinoma and may have potential prognostic value.

Entities:  

Keywords:  endometrial cancer; histone 3 lysine methylation; histone modifications

Year:  2017        PMID: 29113269      PMCID: PMC5661412          DOI: 10.3892/ol.2017.6979

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  44 in total

1.  Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.

Authors:  Weiwei Tan; Lin Wang; Quanping Ma; Mei Qi; Ning Lu; Lili Zhang; Bo Han
Journal:  Prostate       Date:  2015-04-15       Impact factor: 4.104

Review 2.  Recent advances of histone modification in gastric cancer.

Authors:  Wen-Yan Yang; Jing-Liang Gu; Tian-Min Zhen
Journal:  J Cancer Res Ther       Date:  2014-12       Impact factor: 1.805

Review 3.  Adiponectin and Endometrial Cancer: A Systematic Review and Meta-Analysis.

Authors:  Fangxin Zeng; Jinyu Shi; Yang Long; Haoming Tian; Xiaoxi Li; Allan Z Zhao; Rose Fanghong Li; Tao Chen
Journal:  Cell Physiol Biochem       Date:  2015

4.  H3K4me3 interactions with TAF3 regulate preinitiation complex assembly and selective gene activation.

Authors:  Shannon M Lauberth; Takahiro Nakayama; Xiaolin Wu; Andrea L Ferris; Zhanyun Tang; Stephen H Hughes; Robert G Roeder
Journal:  Cell       Date:  2013-02-28       Impact factor: 41.582

5.  Global levels of histone modifications predict prognosis in different cancers.

Authors:  David B Seligson; Steve Horvath; Matthew A McBrian; Vei Mah; Hong Yu; Sheila Tze; Qun Wang; David Chia; Lee Goodglick; Siavash K Kurdistani
Journal:  Am J Pathol       Date:  2009-04-06       Impact factor: 4.307

6.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

7.  Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells.

Authors:  Hong Tao; Haiying Li; Yanhuang Su; Danni Feng; Xilong Wang; Chun Zhang; Hui Ma; Qikuan Hu
Journal:  Mol Cell Biochem       Date:  2014-05-16       Impact factor: 3.396

8.  Ash2L enables P53-dependent apoptosis by favoring stable transcription pre-initiation complex formation on its pro-apoptotic target promoters.

Authors:  S K Mungamuri; S Wang; J J Manfredi; W Gu; S A Aaronson
Journal:  Oncogene       Date:  2014-07-14       Impact factor: 9.867

9.  Erratum to: JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.

Authors:  Li-Liang Li; Ai-Min Xue; Bei-Xu Li; Yi-Wen Shen; Yu-Hua Li; Cheng-Liang Luo; Ming-Chang Zhang; Jie-Qing Jiang; Zu-De Xu; Jian-Hui Xie; Zi-Qin Zhao
Journal:  Breast Cancer Res       Date:  2016-11-21       Impact factor: 6.466

10.  Epigenetic hierarchy within the MAGEA1 cancer-germline gene: promoter DNA methylation dictates local histone modifications.

Authors:  Julie Cannuyer; Axelle Loriot; Grégory K Parvizi; Charles De Smet
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

View more
  5 in total

Review 1.  The role of epigenetic mechanisms in the regulation of gene expression in the cyclical endometrium.

Authors:  Alejandra Monserrat Retis-Resendiz; Ixchel Nayeli González-García; Moisés León-Juárez; Ignacio Camacho-Arroyo; Marco Cerbón; Edgar Ricardo Vázquez-Martínez
Journal:  Clin Epigenetics       Date:  2021-05-25       Impact factor: 6.551

Review 2.  The Biological and Clinical Relevance of Inhibitor of Growth (ING) Genes in Non-Small Cell Lung Cancer.

Authors:  Elisabeth Smolle; Nicole Fink-Neuboeck; Joerg Lindenmann; Freyja Smolle-Juettner; Martin Pichler
Journal:  Cancers (Basel)       Date:  2019-08-06       Impact factor: 6.639

3.  Machine Learning Supports Long Noncoding RNAs as Expression Markers for Endometrial Carcinoma.

Authors:  Ana Carolina Mello; Martiela Freitas; Laura Coutinho; Tiago Falcon; Ursula Matte
Journal:  Biomed Res Int       Date:  2020-01-10       Impact factor: 3.411

Review 4.  Targeting Epigenetic Regulators for Endometrial Cancer Therapy: Its Molecular Biology and Potential Clinical Applications.

Authors:  Futaba Inoue; Kenbun Sone; Yusuke Toyohara; Yu Takahashi; Asako Kukita; Aki Hara; Ayumi Taguchi; Michihiro Tanikawa; Tetsushi Tsuruga; Yutaka Osuga
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923

Review 5.  Research Progress of DNA Methylation in Endometrial Cancer.

Authors:  Ting Xu; Hongmei Ding; Jie Chen; Jiahui Lei; Meng Zhao; Bingyu Ji; Youguo Chen; Songbing Qin; Qinqin Gao
Journal:  Biomolecules       Date:  2022-07-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.